Syndax Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, announced the issuance of inducement awards on June 1, 2025, under its 2023 Inducement Plan. The awards allow eight new employees to purchase up to 119,700 shares of common stock. The stock options will vest over four years, with 25% vesting on the first anniversary of the vesting commencement date, and the remaining shares vesting in equal monthly installments over the following 36 months. These terms are contingent on the employees maintaining their service relationship with the company through the respective vesting dates.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。